Study of a Pandemic Influenza Vaccine

Seqirus400 enrolled

Overview

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next avian influenza pandemic. This study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in healthy adults.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

400

Conditions

Influenza

Interventions

Pandemic influenza vaccineBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy adults Exclusion Criteria: * History of Guillain-Barre syndrome or active neurological disease

Locations (2)

CMAX, a division of IDT Australia

Adelaide, South Australia, Australia

Murdoch Childrens Research Institute

Melbourne, Victoria, Australia

Outcomes

Primary Outcomes

Safety and immunogenicity

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.